Last update 12 Nov 2024

Pegaptanib sodium

Last update 12 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Aptamers

Synonyms

anti-VEGF aptamer, pegaptanib, Pegaptanib octasodium

+ [10]

Target

VEGF

Mechanism

VEGF inhibitors(Vascular endothelial growth factor inhibitors)

Therapeutic Areas

Congenital DisordersEye Diseases

Active Indication

Dystrophy, Macular

Inactive Indication

Originator Organization

Gilead Sciences, Inc.

Active Organization

Pfizer Japan, Inc.

Pfizer Inc.

Gilead Sciences, Inc.

Inactive Organization

Oldtech, Inc.

Bausch & Lomb, Inc.Pfizer Canada ULC

+ [1]

Drug Highest PhaseApproved

First Approval Date

US (17 Sep 2004),

Wet age-related macular degeneration

RegulationOrphan Drug (JP)

Gene Sequence

Sequence Code 31604202

Source: *****

Clinical Trials associated with Pegaptanib sodium

ChiCTR2400090827 / SuspendedPhase 1IIT

A study of the safety, efficacy, and cost-effectiveness of using non-vitrectomised subretinal anti-VEGF injections to treat neovascular age-related macular degeneration

Start Date01 Dec 2024

Sponsor / Collaborator-

NCT06349044 / RecruitingNot ApplicableIIT

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies

Based on the interaction between radiation therapy and immunotherapy and the potential potentiation of Probio-M9 for the treatment of ICIs, this study is planned to design an integrated treatment protocol for the first-line treatment of advanced gastrointestinal tumors through the use of macrofractionated radiotherapy as a means of immune activation, combined with the synergistic effect of Probio-M9 microbial agents and PD-1 inhibitors.

Start Date20 Mar 2024

Sponsor / Collaborator

Zhejiang Cancer Hospital

NCT02321267 / RecruitingPhase 4IIT

Cohort Study of the Clinical Course of Macular Diseases in Kagawa (Kagawa Macula Cohort Study)

Macular diseases often cases severe visual impairment. Recent clinical introduction of anti-vascular endothelial growth factor agents may change the clinical course of various macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic macular edema (DME), and so forth. The advance in vitrectomy improve visual outcomes in some maculae diseases, including epiretinal membrane (ERM), macular hole (MH), vitreomacular traction syndrome (VMTS).
Patients with such macular diseases are registered and are followed up for 5 years with appropriate treatment for each patient. By the analysis of the correlation between initial examinations and final visual acuity, factors associated with good visual prognosis will be elucidated.

Start Date01 Dec 2014

Sponsor / Collaborator

Kagawa University

100 Clinical Results associated with Pegaptanib sodium

100 Translational Medicine associated with Pegaptanib sodium

100 Patents (Medical) associated with Pegaptanib sodium

545

Literatures (Medical) associated with Pegaptanib sodium

01 Aug 2024·Biochemical genetics

A Comprehensive Analysis of NRP1 in Malignancies Provide Therapeutic Implication for Treating Cancer Patients Infected with SARS-CoV-2

Article

Author: Chen, Shuzhao ; Xie, Kunying ; Song, Yiling ; Wang, Yun ; Liang, Yang ; Zhang, Limei

COVID-19 (Coronavirus disease 2019) is caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), which can lead to pneumonia, cytokine storms, and lymphopenia. Patients with cancer are more susceptible to SARS-CoV-2 infection and severe COVID-19 due to immunosuppression. Recent studies have indicated that NRP1 (Neuropilin 1) may act as a novel mediator of SARS-CoV-2 entry into the host cell. As no systematic review has been performed investigating the characteristics of NRP1 in pan-carcinoma, we comprehensively analyzed NRP1 in patients with pan-cancer. Using a bioinformatics approach, we aimed to systematically examine NRP1 expression profiles in both pan-carcinoma and healthy tissues. We found that lung and genitourinary cancers have a relatively higher NRP-1 expression than other cancer patients, suggesting that these patients may be more susceptible to SARS-CoV-2. Our analysis further revealed that NRP1 expression was downregulated in Vero E6 cells, whole blood, lung organoids, testis tissue, and alveolospheres infected with SARS-CoV-2. Notably, NRP1 was associated with immune cell infiltration, immune checkpoint genes, and immune-related genes in most patients with cancer. These findings suggest that, in patients with specific types of cancer, especially lung and genitourinary, high expression of NRP1 contributes to greater susceptibility to SARS-CoV-2 infection and an increased risk of damage due to cytokine storms. Overall, NRP1 appears to play a critical role in regulating immunological properties and metabolism in many tumor types. Specific inhibitors of the NRP1 antigen (pegaptanib, EG00229, or MNRP1685A) combined with other anti-SARS-CoV-2 strategies may aid in treating patients with lung and genitourinary cancers following SARS-CoV-2 infection.

16 Apr 2024·Current diabetes reviews

Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview

Article

Author: Gowthamarajan, K ; Khandelwal, Aman ; Nirmal, Jayabalan ; Ponnusankar, S

Abstract::

The discovery of antivascular endothelial growth factor medications has resulted in a substantial change in diabetic retinopathy treatment. The most common cause of diabetic retinopathy blindness is Diabetic Macular Edema. The pathophysiology of Diabetic Macular Edema is thought to include the well-known pro-angiogenic and pro-permeability factor vascular endothelial growth factor. Over the past decade, drugs that impede the functions of vascular endothelial growth factors have established themselves as a standard-of-care treatment for a range of ocular ailments and improved patients' clinical results with diabetic retinopathy and Diabetic Macular Edema, and their frequency has grown exponentially with the introduction of these agents Pegaptanib, Ranibizumab, and Aflibercept which are approved for ophthalmic indications, while Bevacizumab is used off-label. These medications delivered intravitreally have halted the vascular development of diabetic retinopathy. Various randomized trials have proven that antivascular endothelial growth factor medication is safe and effective in preserving vision. Following an extensive period of preclinical development aimed at enhancing and defining its biological impacts, these drugs were shown in clinical trials to be effective in treating diabetic retinopathy and other ophthalmic conditions. Data from various sources suggest that Pegaptanib, Ranibizumab, and Aflibercept are costly, while Bevacizumab is cost-effective, and in low and middle-income nations, it is thus a desirable therapy choice. However, issues with compounding, counterfeiting, and off-label usage restrict its availability in many nations. The pharmacology, pharmacokinetics, pharmacodynamics, adverse effects, and contraindications of antivascular endothelial growth factor agents are discussed, and the results of clinical trials evaluating their efficacy are summarized.

03 Mar 2024·Expert opinion on drug safety

A real-world disproportionality analysis of anti-VEGF drugs from the FDA Adverse Event Reporting System

Article

Author: Chen, Junheng ; Lu, Peiwen ; Han, Fangfang ; Zhou, Ruishan ; He, Mingxiu ; Shi, Yiyang ; Cai, Yongming

BACKGROUND:

The association between anti-vascular endothelial growth factor (VEGF) drugs and ocular adverse events (AEs) has been reported, but large real-world studies of their association with systemic AEs are still lacking.

METHODS:

A disproportionality analysis of reports from the FDA Adverse Event Reporting System from January 2004 to September 2021 was conducted to detect the significant ADR signals with anti-VEGF drugs (including aflibercept, bevacizumab, brolucizumab, pegaptanib, and ranibizumab).

RESULTS:

A total of 2980 reported cases with 7125 drug-AEs were included. Five drugs were all associated with eye disorders, and pegaptanib and ranibizumab were also associated with cardiac disorders. For ranibizumab, pegaptanib, bevacizumab and aflibercept, the proportions of cardiac AEs were 8.57%, 5.62%, 3.43% and 3.20%, respectively, and the proportions of central nervous AEs were 8.81%, 7.41, 5.86% and 5.68%, respectively. In multiple comparisons, ranibizumab was significantly higher than bevacizumab and aflibercept in the proportion of cardiac AEs (P < 0.001), and ranibizumab was significantly higher than aflibercept in central nervous AEs (P < 0.001).

CONCLUSIONS:

Our findings support the associations between anti-VEGF drugs and ocular AEs, cardiac AEs, and central nervous AEs. After intravitreal injection, attention should not only be paid to ocular symptoms, but also to systemic symptoms.

News (Medical) associated with Pegaptanib sodium

04 Sep 2024

·www.globenewswire.com

iSTAR Medical continues to strengthen US presence with appointment of Chief Medical Officer and Vice President of Clinical Affairs

For immediate release iSTAR Medical continues to strengthen US presence with appointment of Chief Medical Officer and Vice President of Clinical Affairs WAVRE, Belgium — 4 September 2024: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces the strengthening of its leadership team with the appointment of Richard (Rick) Beckman, M.D., as Chief Medical Officer and member of the Board, and Kristine (Kris) Curtiss as Vice President of Clinical Affairs. Rick’s duties as Chief Medical Officer (CMO) will cross clinical, regulatory, and medical affairs. Additionally, he will be a member of the Board. Rick brings deep insight and experience from his previous roles as a CMO, most recently at Adverum, and has an extensive background in the medical and surgical management of glaucoma as well as in glaucoma pharmaceutical and device development. Based in the US, he will be critical to the successful development of the Company’s clinical programs and will report to the Chief Executive Officer (CEO), Michel Vanbrabant. Kaweh Mansouri, M.D., who is stepping down as CMO to focus on his appointment as Executive Vice President of the World Glaucoma Association, will continue as a consultant to the Company as a Senior Medical Advisor. Kris joins the leadership team as Vice President (VP) of Clinical Affairs with over 20 years of clinical research experience and having held senior positions in biotech, medical device, and large pharma companies. She will lead iSTAR Medical’s clinical organization including its STAR-V trial and will report to the CMO, Rick Beckman. David Stocker, who held the role of VP of Clinical Affairs will return to his previous responsibilities in the commercial organization as VP Sales, Marketing, and Training. Michel Vanbrabant, CEO of iSTAR Medical, commented: “We are delighted to welcome Rick and Kris to our leadership team. Their combined global experience in clinical, regulatory, and medical affairs will be instrumental in guiding the Company towards delivering breakthrough eye care solutions to a greater number of patients in additional global territories. “I want to extend my gratitude to Kaweh for his significant contributions to iSTAR Medical thus far, which has helped us establish a global reputation for MINIject® as a safe and effective treatment option for glaucoma patients. We congratulate him and wish him the best of luck with his role as Executive Vice President of the World Glaucoma Association.” Richard Beckman, M.D., Chief Medical Officer and member of the BoardRick, a board-certified ophthalmologist and fellowship trained glaucoma specialist, is a seasoned professional with extensive experience in the healthcare and biotechnology sectors. He was previously CMO at Adverum Biotechnologies, ReNeuron, as well as Clearside Biomedical. He was formerly the head of the glaucoma therapeutic area at Alcon. Rick is currently the principal at RLB, M.D., Consulting and serves on the Board of OceanZero US. He holds an M.D. from University of Michigan, completing his ophthalmology residency at Henry Ford Hospital, after which he completed a glaucoma fellowship at Massachusetts Eye and Ear Infirmary/Harvard Medical School. Kristine Curtiss, Vice President of Clinical AffairsKris joins the iSTAR Medical team with extensive experience in clinical research and ophthalmology. She was previously VP Clinical Operations at Iveric Bio, Inc., and prior to that she held leadership positions at ophthalmic start-ups including PanOptica, Oraya Therapeutics, and OPKO. During her career, Kris has been a major contributor to 5 successful marketing applications, including Iverzay™ for Geographic Atrophy and Macugen® for exudative Age-related Macular Degeneration. She holds a Bachelor of Science in Chemistry from the University of Delaware and a graduate certificate in Project Management from Rutgers University School of Business. – Ends – For more information Paul van HagenChief Financial Officer, iSTAR Medicalnews@istar-medical.com For mediaICR ConsiliumAmber Fennell, Chris Welsh, Kris LamiSTAR@consilium-comms.com About iSTAR Medical iSTAR Medical is committed to delivering breakthrough eye care solutions. Our most advanced product, MINIject®, is approved in Europe for the treatment of open-angle glaucoma – the leading cause of irreversible blindness – and we are aiming to seek market approval in the US. We believe MINIject®’s distinctive tissue-integrating capabilities unlock a safer, and more effective option for patients. We are building an exceptional team and pipeline of potentially leading products such as MINIject® to establish new treatment paradigms in eye care conditions with the highest patient needs. iSTAR Medical is an independent company which entered a strategic partnership with AbbVie (NYSE: ABBV) in July 2022. The collaboration further supports the role of MINIject® in the treatment of glaucoma and accelerates iSTAR Medical’s goal to bring MINIject® to more patients globally while providing AbbVie the opportunity to further expand its diverse eye care portfolio. About MINIject® MINIject® is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. MINIject® combines the distinctive porous structure of its proprietary STAR material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications. About GlaucomaGlaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form.1,2 IOP reduction, through medication or surgery, helps delay disease progression.3 Medication is generally the first line treatment, but the progressive addition of multiple drops can burden patients with side effects, compliance challenges and costs.2,3 Invasive surgery can present risks with irreversible complications and often requires long-term patient management.2,3 MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile.2 MINIject® is potentially best-in-class for its promising long-term efficacy and safety. 1 Jonas JB, Aung T, Bourne RR et al. "Glaucoma". Lancet 2017; 390: 2083–932 Market Scope, “2023 Glaucoma Surgical Device Market Report”, July 2023. 3 “European Glaucoma Society Terminology and Guidelines for Glaucoma”, 4th Edition: British Journal of Ophthalmology. 2017;101:1-195 https://bjo.bmj.com/content/101/5/73

Executive Change

16 Apr 2024

·www.globenewswire.com

Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.

Ophthalmology industry veteran brings 20 years of experience as a life science investor and entrepreneur to Nacuity’s boardFORT WORTH, Texas, April 16, 2024 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel treatments for retinitis pigmentosa, cataract, and other diseases caused by oxidative stress, today announced the appointment of Emmett T. Cunningham, Jr., M.D., Ph.D., MPH, to its board of directors. Dr. Cunningham is currently a Senior Partner at HealthQuest Capital Management and co-founder and Executive Chairman of Eyconis, Inc., a spinout of Ascendis Pharma created to develop, manufacture, and commercialize TransCon ophthalmology assets globally. “We’re thrilled to welcome Dr. Cunningham to our board of directors,” said Halden Conner, Chairman, CEO and Co-Founder of Nacuity Pharmaceuticals. “His career as a prominent leader in the ophthalmology industry, bridging the business world and ophthalmic innovation, will be a vital asset at this pivotal time for our clinical programs in oxidative stress.” Dr. Cunningham is an ophthalmology industry veteran with over 20 years of experience as a full-time investor and entrepreneur who has led or co-led investments and partnerships in the medical device and biotechnology space that have supported the FDA approval of multiple therapeutics. He is also an internationally recognized specialist in infectious and inflammatory eye disease with over 400 publications. “Nacuity’s approach to treating ophthalmic and non-ophthalmic disorders is both completely novel and tremendously promising,” said Dr. Cunningham. “I look forward to working with the Nacuity team to unlock the broad therapeutic potential of its clinical programs in treating ocular and non-ocular disease.” Prior to HealthQuest and Eyconis, Dr. Cunningham served as a Senior Managing Director at Blackstone, Inc. following that firm’s acquisition of Clarus Ventures in 2018. At Clarus, Dr. Cunningham was a member of the full-time investment team since the firm’s inception in 2006. From 2001 to 2005, Dr. Cunningham was the Senior Vice President of Medical Strategy at Eyetech Pharmaceuticals, Inc., where he was part of the leadership team that developed Macugen®, a first-in-class VEGF-A inhibitor for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc. In addition, Dr. Cunningham was the co-founder and chairman of the Ophthalmology Innovation Summit (OIS). He received an M.D. and MPH in epidemiology and statistics from Johns Hopkins University and a Ph.D. in neuroscience from the University of California at San Diego for work done at The Salk Institute. Dr. Cunningham is a member of the board of directors of Galera Therapeutics and Executive Chairman of Eyconis. He serves as Innovator in Residence for Johns Hopkins Technology Ventures (JHTV); as a member of the Biomedical Engineering Advisory Board at Johns Hopkins University; is an advisor to the Byers Center for BioDesign at Stanford University; and serves philanthropically on the Boards of The Alta Foundation and EverythingALS. About Nacuity Pharmaceuticals, Inc. Nacuity Pharmaceuticals, Inc. (https://www.nacuity.com/), is a clinical-stage leader in innovative treatments for diseases produced by oxidative stress. The company’s powerful, targeted therapies aim to attenuate oxidative tissue damage, a driver of blinding eye diseases and a broad spectrum of serious chronic conditions. Nacuity has three highly differentiated, first-in-class clinical development programs ongoing in retinitis pigmentosa, cataract and inherited cystinosis. Nacuity has operations in Fort Worth, TX, USA, and Australia, and extensive managerial and scientific domain expertise as well as backing from Foundation Fighting Blindness (https://www.fightingblindness.org/) and its venture arm RD Fund (https://www.retinaldegenerationfund.org). Nacuity Media ContactJulia Clements267.626.1085jclements@6degreespr.com

Executive ChangeAcquisition

16 Oct 2023

·www.biospace.com

Opinion: Interest in RNA Editing Accelerates as Therapies Approach the Clinic

Pictured: RNA/iStock, Artur Plawgo Based on the significant progress made over the last few decades with RNA therapeutics, RNA editing is widely considered the next generation of promising medicines in this field. RNA therapies have made significant progress over the last few years, with an increasing number of FDA approvals beginning in 1998 with Vitravene for CMV retinitis, followed by Macugen for macular degeneration in 2004 and Spinraza for spinal muscular atrophy in 2016. There have also been multiple siRNA-based drugs, including Onpattro for polyneuropathy of hereditary transthyretin-mediated amyloidosis in 2018. And finally, in 2020, perhaps the most well-known products in the RNA space were introduced: the mRNA-based COVID-19 vaccines. All of these demonstrate the strength of RNA therapies and their potential impact on diseases with high unmet need. RNA therapeutics are indeed elegant approaches to altering RNA and thus protein expression, opening the potential to target a broad array of diseases. The field has seen a renewed and increased interest as reversible changes offer flexibility and RNA approaches introduce therapeutic opportunities that were not accessible before. RNA editing technology was first known and recognized as an interesting approach to treating genetic conditions and reversing disease-causing mutations at the RNA level. RNA editing is a naturally occurring and highly active process that uses the body’s existing capabilities to perform nucleotide changes. Since 2014, when ProQR Therapeutics invented the technique of using oligonucleotides recruiting endogenous adenosine deaminase action on RNA, known as ADAR-mediated editing, the field has rapidly progressed. This growth can be attributed to the rapid progression of knowledge about the technology. Alpha-1 antitrypsin deficiency (AATD) is the first indication that many RNA editing companies have decided to pursue, as it provides the opportunity to address liver and lung symptoms of the disease. Clinical trials for AATD run by both Wave Life Sciences and Korro Bio are planned to begin this year and next. Genetic and Common Disorders There is great excitement in the field about using learnings from decades of oligonucleotide-based drug development, natural RNA editing, and knowledge of biological pathways to make RNA editing technology a compelling approach to target various pathophysiological processes. This offers, for example, the possibility not only of reducing or restoring protein expression but also of modulating protein activity involved in diseases. This application of RNA editing offers the potential to impact both genetic disorders and common conditions, such as metabolic and cardiovascular diseases. ProQR’s approach differentiates RNA editing, as it provides the opportunity to target conditions that have thus far not been treatable with other technologies. Indeed, RNA editing offers the possibility of introducing protective variants, informed by human genetics, that could address or prevent diseases including certain cholestatic or cardiovascular conditions. For example, it has been reported in the literature that an Old Order Amish-enriched variant in a functional B4GALT1 was associated with lower serum LDL-C and lower plasma fibrinogen. This protective variant can be introduced via ADAR RNA editing technology, which has the potential to simultaneously address the two cardiovascular risk factors. Delivery is an important aspect of oligonucleotide base therapeutics. RNA therapies, including RNA editing, have again made great progress and generally use conjugation or lipid nanoparticle approaches. As an example, Alnylam made tremendous progress in its siRNA-based treatments for amyloidosis, with Onpattro in 2018 offering an intravenous treatment once every three weeks. Only four years later, Amvuttra arrived on the market for the same condition but with a subcutaneous 3-month dosing approach. For now, the majority of RNA editing programs are focused on targeting the liver where delivery is relatively de-risked, although progress is also being made in exploring new frontiers such as the central nervous system, as evidenced by the partnerships between Roche and Shape Therapeutics and ProQR and Eli Lilly. In summary, the RNA editing space is making impressive progress. The recent approvals and clinical results demonstrating the potential of RNA therapy to target a broad array of organs are extremely encouraging for RNA editing. Near term, we expect to see further development of the technology, more programs advancing to clinical development, expansion of therapeutic areas addressed, and ultimately, we are hopeful that the next few years will bring considerable progress for patients in need. Gerard Platenburg is a cofounder of ProQR and has served as the company’s chief scientific officer since 2022. Gerard has an extensive background in RNA modulation and orphan drug discovery and development and currently leads ProQR's Innovation unit.

OligonucleotideDrug ApprovalsiRNAVaccinemRNA

100 Deals associated with Pegaptanib sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D05386	Pegaptanib sodium	S01LA03	DB04895

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dystrophy, Macular	CA	Pfizer Canada ULC	26 Aug 2005
Wet age-related macular degeneration	US	Bausch & Lomb, Inc.	17 Sep 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ovarian Cancer	Phase 3	FI	Pfizer Inc.	01 Jan 2011
Ovarian Cancer	Phase 3	ES	Pfizer Inc.	01 Jan 2011
Ovarian Cancer	Phase 3	SE	Pfizer Inc.	01 Jan 2011
Ovarian Cancer	Phase 3	GB	Pfizer Inc.	01 Jan 2011
Macular Edema	Phase 3	JP	Pfizer Inc.	01 May 2010
Age Related Macular Degeneration	Phase 3	DE	Pfizer Inc.	01 Nov 2008
Diabetic macular oedema	Phase 3	US	Pfizer Inc.	01 Sep 2005
Diabetic macular oedema	Phase 3	AU	Pfizer Inc.	01 Sep 2005
Diabetic macular oedema	Phase 3	BR	Pfizer Inc.	01 Sep 2005
Diabetic macular oedema	Phase 3	CA	Pfizer Inc.	01 Sep 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01573572 (CTgov)	Phase 4	Diabetic macular oedema \| Age Related Macular Degeneration \| Retinal Vein Occlusion	131	pegaptanib sodium injection	zmtdymhfyh(wszzwiuhya) = vbtmogfifn xlppuaoudr (jaifqhlrnl, szkbksytpl - hznwlclxdy) View more	-	14 Oct 2020
NCT00790803 (CTgov)	Not Applicable	Uveitis \| Macular Edema	5	Pegaptanib (Macugen)	coyekzxqry(pxpbrqqazk) = faszehwqup hudyekbqys (fcxptpuqba, ietynygtas - yzvynnuzca) View more	-	26 Sep 2013
NCT01189461 (CTgov)	Phase 3	Diabetic macular oedema	46	Macugen (pegaptanib sodium)	eeazylniwk(iiinauyndd) = fizsyeoyty xyuixlcdws (fpgwuqirea, dxltiluwpx - blrlqxjugx) View more	-	06 Sep 2013
NCT01100307 (CTgov)	Phase 3	Diabetic macular oedema \| Macular Edema	243	pegaptanib sodium	cjpcdhfqyr(hhdkgcohfd) = xhoehjrvmg exshpspvzv (irjzxwnmcu, ncsrrvvexk - jqlkdihedo) View more	-	15 Jul 2013
phase II study (ARVO2013)	Phase 2	Proliferative retinopathy with diabetes mellitus	-	Pegaptanib+Progressive PRP	zxpembnjyt(llrtfakyul) = vcllzpkjlq rruksyxjjf (cgibjrzigy )	Positive	01 Jun 2013
phase II study (ARVO2013)	Phase 2	Proliferative retinopathy with diabetes mellitus	-	Pegaptanib	zxpembnjyt(llrtfakyul) = zvxitgdlpr rruksyxjjf (cgibjrzigy )	Positive	01 Jun 2013
ARVO2013	Not Applicable	-	30	Pegaptanib	gwqmjjaayd(jfwajvfnpx) = pisuvlzyad obpxfowxpd (flvsvuskkw ) View more	Negative	01 Jun 2013
ARVO2013	Not Applicable	Proliferative retinopathy with diabetes mellitus	20	Pegaptanib	apxbvubgyg(tdmgvwrppa) = klxodiiubp mmsitsluku (kxkmgrgtfj )	Positive	01 Jun 2013
ARVO2013	Not Applicable	Diabetic macular oedema ischemia	30	Pegaptanib	bjsygjrknv(sxujitcerk) = cwbatyegts ardkjacnsv (wsflqurodz ) View more	Negative	01 Jun 2013
ARVO2013	Not Applicable	Retinal Neovascularization	30	Intravitreal pegaptanib sodium	gzngdnkyby(iqvwqzhtvs) = One patient in group B efcdkyvtxu (hmbwegaqar ) View more	Positive	01 Jun 2013
ARVO2013	Not Applicable	Retinal Neovascularization	30	Anti-VEGF		Positive	01 Jun 2013
RIH 1006 (ARVO2012)	Not Applicable	Retinal oedema vascular endothelial growth factor (VEGF)	4	Intravitreal pegaptanib sodium 0.3 mg every 2 weeks for 3 doses, every 3 weeks for 2 doses, and then every 4 weeks for 3 doses	oqsccbgjbu(bzvztwsxth) = wtswyuwosr oxfxtilqnd (pqcnhvklus )	-	01 Mar 2012

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis